blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3825309

EP3825309 - SALT OF LSD1 INHIBITOR AND A POLYMORPH THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.07.2024
Database last updated on 10.05.2025
FormerThe patent has been granted
Status updated on  04.08.2023
FormerGrant of patent is intended
Status updated on  22.03.2023
FormerRequest for examination was made
Status updated on  23.04.2021
FormerThe international publication has been made
Status updated on  25.01.2020
Most recent event   Tooltip07.02.2025Lapse of the patent in a contracting state
New state(s): MC		published on 12.03.2025  [2025/11]
Applicant(s)For all designated states
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
226 Huanghe Street
High-Tech Development Zone
Shijazhuang
Hebei 050035 / CN
[2021/21]
Inventor(s)01 / ZHAO, Lele
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
02 / SUN, Jianjun
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
03 / WU, Lingyun
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
04 / CHEN, Shuhui
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
 [2021/21]
Representative(s)Petraz, Gilberto Luigi, et al
GLP S.r.l.
Viale Europa Unita, 171
33100 Udine / IT
[2021/21]
Application number, filing date19837636.019.07.2019
[2021/21]
WO2019CN96842
Priority number, dateCN20181080406820.07.2018         Original published format: CN201810804068
[2021/21]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020015745
Date:23.01.2020
Language:ZH
[2020/04]
Type: A1 Application with search report 
No.:EP3825309
Date:26.05.2021
Language:EN
[2021/21]
Type: B1 Patent specification 
No.:EP3825309
Date:06.09.2023
Language:EN
[2023/36]
Search report(s)International search report - published on:CN23.01.2020
(Supplementary) European search report - dispatched on:EP18.02.2022
ClassificationIPC:C07D271/06, A61K31/4245, A61P35/00
[2022/12]
CPC:
A61K31/4245 (EP,KR); C07D271/06 (EP,KR,US); A61P35/00 (EP,KR,US);
C07B2200/13 (KR,US)
Former IPC [2021/21]C07D271/06, A61K31/13, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/21]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:SALZ EINES LSD1-INHIBITORS UND POLYMORPH DAVON[2021/21]
English:SALT OF LSD1 INHIBITOR AND A POLYMORPH THEREOF[2021/21]
French:SEL D'INHIBITEUR DE LSD1 ET POLYMORPHE DE CELUI-CI[2021/21]
Entry into regional phase18.01.2021Translation filed 
18.01.2021National basic fee paid 
18.01.2021Search fee paid 
18.01.2021Designation fee(s) paid 
18.01.2021Examination fee paid 
Examination procedure18.01.2021Examination requested  [2021/21]
07.09.2022Amendment by applicant (claims and/or description)
23.03.2023Communication of intention to grant the patent
27.07.2023Fee for grant paid
27.07.2023Fee for publishing/printing paid
27.07.2023Receipt of the translation of the claim(s)
Opposition(s)07.06.2024No opposition filed within time limit [2024/33]
Fees paidRenewal fee
05.05.2021Renewal fee patent year 03
31.05.2022Renewal fee patent year 04
02.05.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.09.2023
BG06.09.2023
CZ06.09.2023
DK06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
MC06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SI06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
[2025/11]
Former [2024/51]AT06.09.2023
BG06.09.2023
CZ06.09.2023
DK06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SI06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/36]AT06.09.2023
CZ06.09.2023
DK06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SI06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/33]AT06.09.2023
CZ06.09.2023
DK06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/26]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/25]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/23]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/20]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RS06.09.2023
SE06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
Former [2024/14]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RS06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/10]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RS06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/09]FI06.09.2023
LT06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/08]LT06.09.2023
NO06.12.2023
GR07.12.2023
Documents cited:Search[A]WO2010084160  (ORYZON GENOMICS SA [ES], et al);
 [A]WO2012013728  (ORYZON GENOMICS SA [ES], et al);
 [XPA]WO2018137644  (MEDSHINE DISCOVERY INC [CN])
International search[A]CN102947265  (ORYZON GENOMICS SA);
 [A]CN103857393  (GLAXOSMITHKLINE LLC);
 [A]WO2017184934  (INCYTE CORP [US]);
 [A]WO2017195216  (JUBILANT BIOSYS LTD [IN]);
 [PX]WO2018137644  (MEDSHINE DISCOVERY INC [CN])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.